3SBio Inc., of Shenyang, China, entered an exclusive license agreement with pegylation services company Jenkem Technology Co. Ltd. for the development, manufacturing and marketing in mainland China of peg-irinotecan, a long-acting polymer-drug conjugate inhibiting topoisomerase I, which is overexpressed in many solid tumors.